$319.4M in CY2024 Part D spend8K claims · 6K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Ocrelizumab used for?
Ocrelizumab targets CD20-positive cells to treat certain lymphomas and autoimmune conditions.
Is there a generic for Ocrelizumab?
No. Ocrelizumab is brand-only with no generic equivalents currently in market.
How much does my plan pay for Ocrelizumab?
NADAC pricing data not currently available for this drug.
Is Ocrelizumab on the FDA shortage list?
No. Ocrelizumab is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.